Metformin Monotherapy Not Always Best Start in Type 2 Diabetes Metformin Monotherapy Not Always Best Start in Type 2 Diabetes
Findings suggest that at time of type 2 diabetes diagnosis some might not benefit from metformin as first-line treatment. Dual or other therapy may be preferable.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 16, 2023 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news

NPPA revises ceiling prices of 128 formulations
The National Pharmaceutical Pricing Authority (NPPA) has also fixed the retail price of 12 scheduled formulations under Drugs (Prices Control) Order, 2013 (NLEM 2022). The retail price of one tablet of anti-diabetes combination drug Glimepiride, Voglibose& Metformin (extended release) has been fixed at Rs 13.83. Similarly, retail price of one tablet of Paracetamol, Phenylephrine Hydrochloride, Diphenhydramine Hydrochloride and Caffeine has been fixed at Rs 2.76. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 16, 2023 Category: Pharmaceuticals Source Type: news

Costs of 127 medicines set to go down post NPPA's 5th price cap
Among the 127 medications on the NPPA's list are paracetamol, amoxycillin, rabeprazole, and metformin. Patients frequently make use of many of these. The price of paracetamol (650 mg), which is sold for Rs 2.3 per tablet, has been restricted at Rs 1.8. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 22, 2022 Category: Pharmaceuticals Source Type: news

Can Metformin Lower Need for Joint Replacement in Diabetes? Can Metformin Lower Need for Joint Replacement in Diabetes?
Patients with type 2 diabetes who were treated with metformin had a 30% reduction in risk for total knee and total hip replacement, compared with patients who did not receive the drug.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 20, 2022 Category: Allergy & Immunology Tags: Diabetes & Endocrinology News Source Type: news

Metformin Use Linked to Lower Risk for Joint Replacement in T2DM
MONDAY, Dec. 19, 2022 -- For patients with type 2 diabetes, metformin use is associated with a reduced risk for total knee replacement (TKR) and total hip replacement (THR), according to a study published online Dec. 19 in CMAJ, the journal of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 19, 2022 Category: Pharmaceuticals Source Type: news

Metformin Protective Against Joint Replacement in Type 2 Diabetes
(MedPage Today) -- Among people with type 2 diabetes, use of metformin might help to stave off total joint replacement, a population-based cohort study showed. Among over 40,000 patients, daily metformin was associated with a 30% lower risk for... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 19, 2022 Category: Urology & Nephrology Source Type: news

Torrent Pharmaceuticals partner with Boehringer Ingelheim to co-market diabetes, cardiovascular medicines
Both companies entered into partnership for the sales and co-marketing of Empagliflozin and its combinations including Cospiaq (Empagliflozin), Cospiaq MetTM (Empagliflozin+ Metformin) and Xilingio (Empagliflozin+ Linagliptin) in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 14, 2022 Category: Pharmaceuticals Source Type: news

R-Form Verapamil Added to Ongoing Metformin Therapy in T2D R-Form Verapamil Added to Ongoing Metformin Therapy in T2D
A new study examines the potential of this combination therapy as a treatment option for patients with type 2 diabetes who do not adequately respond to metformin alone.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2022 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Diabetes Drug Metformin Might Keep Severe COVID Away
WEDNESDAY, Nov. 23, 2022 -- A century-old diabetes drug seems to help keep high-risk COVID-19 patients from falling deathly ill, a new study reports. Metformin reduced the risk of death from COVID-19 by 44% in a group of diabetics who were taking... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 23, 2022 Category: General Medicine Source Type: news

Ceramides to Predict Metabolic Response to Metformin in PCOS Ceramides to Predict Metabolic Response to Metformin in PCOS
What could ceramide concentrations tell us about the metabolic response to metformin treatment in these women?Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 22, 2022 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

SPRINT BP Control Benefit Fizzles Out; Hot Flashes and CVD; Metformin for Afib?
(MedPage Today) -- In a new policy statement, the American College of Cardiology endorsed more flexible hours and work arrangements so that cardiologists and trainees can have a better work-life balance. High-intensity care following heart failure... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 18, 2022 Category: Cardiology Source Type: news

Glitazones & Dementia; Diabetes Insipidus Name Change? Islet Transplant Success
(MedPage Today) -- A study of U.S. veterans with type 2 diabetes found that those treated with thiazolidinedione had a 22% reduced risk of all-cause dementia versus metformin, while those treated with a sulfonylurea saw a 12% higher risk. (BMJ... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - October 18, 2022 Category: Endocrinology Source Type: news

Thiazolidinedione Monotherapy for T2DM Tied to Lower Dementia Risk
WEDNESDAY, Oct. 12, 2022 -- For patients with type 2 diabetes (T2D), thiazolidinedione (TZD) monotherapy is associated with reduced dementia risk compared with metformin (MET) monotherapy, while sulfonylurea (SU) monotherapy is associated with an... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 12, 2022 Category: Pharmaceuticals Source Type: news

One Type of Older Diabetes Drug Cuts Dementia Risk, Another Ups It One Type of Older Diabetes Drug Cuts Dementia Risk, Another Ups It
Observational study data suggest thiazolidinediones may be protective when it comes to dementia risk in patients with type 2 diabetes, whereas sulfonylureas increase the risk, compared with metformin.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 11, 2022 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

Common diabetes drugs may fight dementia, atrial fibrillation, studies suggest
A class of Type 2 diabetes drugs called glitazones is linked to a 22% reduced risk of dementia, says research led by the University of Arizona. Cleveland Clinic scientists said metformin may treat atrial fibrillation. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 11, 2022 Category: Consumer Health News Source Type: news